Systemic steroid treatment can desensitize the skin reaction due to regorafenib in a recurrence colorectal cancer patient.
Continuous steroid intake
Erythema multiforme
Metastatic colorectal cancer
Rechallenge chemotherapy
Regorafenib
Supportive therapy
Journal
International cancer conference journal
ISSN: 2192-3183
Titre abrégé: Int Cancer Conf J
Pays: Singapore
ID NLM: 101734231
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
29
03
2019
accepted:
15
05
2019
entrez:
28
9
2019
pubmed:
29
9
2019
medline:
29
9
2019
Statut:
epublish
Résumé
Oral intake of regorafenib has been shown to have survival benefits in patients with metastatic colorectal cancer progressing on standard therapies. However, because of adverse effects, the patients sometimes cannot continue treatment with regorafenib. Currently, there is no established supportive therapy that can be performed to aid in continuing regorafenib intake under these problematic conditions. We report the case of a 59-year-old Japanese woman diagnosed with recurrence after curative operation for sigmoid colon cancer (T3N2aM0, Stage IIIC). Despite undergoing multiple lines of standard chemotherapy, disease control could not be maintained. Consequently, regorafenib was started as a late-line treatment. However, after 2 weeks, the patient experienced regorafenib-induced serious erythema multiforme; thus, regorafenib was discontinued and oral prednisolone was started. Regorafenib administration was resumed when the adverse effects resolved and prednisolone was stopped, but skin rash rapidly reappeared. Prednisolone treatment was reintroduced, which cured the rash; thus, after the third attempt to administer regorafenib, prednisolone was continuously administered. There was no relapse of the rash under prednisolone administration, and the patient received a total of 13 courses of regorafenib. Moreover, the metastatic lesions that had started to regrow at the end of the regorafenib therapy showed good response to the rechallenge chemotherapy of folinic acid, fluorouracil, and irinotecan therapy with panitumumab. The sequence of therapies possibly had a positive impact on the patient's long survival of 30 months after the regorafenib treatment. Systemic administration of steroid is considered as a promising option as a supportive therapy for continuing regorafenib treatment in patients experiencing a severe skin rash.
Identifiants
pubmed: 31559116
doi: 10.1007/s13691-019-00376-4
pii: 376
pmc: PMC6744540
doi:
Types de publication
Case Reports
Langues
eng
Pagination
164-169Déclaration de conflit d'intérêts
Conflict of interestThe authors declare that they have no conflict of interest.
Références
J Clin Oncol. 2008 Sep 1;26(25):4217-9
pubmed: 18757341
Acta Derm Venereol. 2008;88(6):627-8
pubmed: 19002355
Clin Cancer Res. 2010 Feb 1;16(3):790-9
pubmed: 20103678
Ann Oncol. 2012 Sep;23(9):2313-8
pubmed: 22396447
Lancet. 2013 Jan 26;381(9863):303-12
pubmed: 23177514
J Exp Clin Cancer Res. 2013 Nov 18;32:92
pubmed: 24245912
Int J Clin Oncol. 2015 Jun;20(3):566-73
pubmed: 25030546
Gan To Kagaku Ryoho. 2014 Nov;41(12):1841-3
pubmed: 25731348
Therap Adv Gastroenterol. 2015 Sep;8(5):285-97
pubmed: 26327919
Drug Des Devel Ther. 2015 Nov 11;9:6067-73
pubmed: 26648694
J Chemother. 2017 Apr;29(2):102-105
pubmed: 28032528
Int J Clin Oncol. 2018 Feb;23(1):1-34
pubmed: 28349281
J Gen Fam Med. 2017 Mar 24;18(2):90-91
pubmed: 29263999